Combination Analgesic Development for Enhanced Clinical Efficacy (CADENCE Trial): Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of an Alpha-Lipoic Acid – Pregabalin Combination for the Treatment of Fibromyalgia Pain

Readers: No access to all 28 journals. We recommend accessing our articles via PubMed Central
Authors: No access to the submission form or your user account.
Reviewers: No access to your user account. Please download manuscripts you are reviewing for offline reading before Wednesday, July 01, 2020 at 7:00 PM .
Editors: No access to your user account to assign reviewers or make decisions.
Copyeditors: No access to user account. Please download manuscripts you are copyediting before Wednesday, July 01, 2020 at 7:00 PM .

Works citing "Combination Analgesic Development for Enhanced Clinical Efficacy (CADENCE Trial): Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of an Alpha-Lipoic Acid – Pregabalin Combination for the Treatment of Fibromyalgia Pain"

Ian Gilron, Dongsheng Tu, Ronald Holden, Tanveer Towheed, Elizabeth Vandenkerkhof, Roumen Milev

JMIR Res Protoc 2017 (Aug 04); 6(8):e154

According to Crossref, the following articles are citing this article (DOI 10.2196/resprot.8001):

(note that this is only a small subset of citations)

Schweiger V, Secchettin E, Castellani C, Martini A, Mazzocchi E, Picelli A, Polati E, Donadello K, Valenti MT, Dalle Carbonare L. Comparison between Acupuncture and Nutraceutical Treatment with Migratens® in Patients with Fibromyalgia Syndrome: A Prospective Randomized Clinical Trial. Nutrients 2020;12(3):821
CrossRef
Gilron I, Robb S, Tu D, Holden RR, Milev R, Towheed T. Combination analgesic development for enhanced clinical efficacy (the CADENCE trial): a double-blind, controlled trial of an alpha-lipoic acid–pregabalin combination for fibromyalgia pain. Pain 2023;164(8):1783
CrossRef